Paclitaxel Liposome And Docetaxel Combined With Carboplatin In Advanced Epithelial Ovarian Cancer Treatment Efficacy And Safety Of Observation

ObjectiveObservation of paclitaxel liposome and docetaxel combined with carboplatin in advanced epithelial ovarian cancer patients with 2 cycles of chemotherapy efficacy and safety.MethodsRandomly selected 58 patients with advanced epithelial ovarian cancer patients, randomly selected groups, paclitaxel liposome group:A total of 26 chemotherapy using paclitaxel liposome 135mg/m2; docetaxel group:A total of 32, with docetaxel 75mg/m2 chemotherapy. Both groups were combined with carboplatin area under the curve (AUC)= 5 (Calvert formula),21 d was 1 cycle,2 cycles of treatment, and follow-up clinical events were recorded, according to WHO criteria to evaluate the objective response and toxicity.ResultsPaclitaxel liposome group, three cases of flapping CR,73.1%efficiency (19/26), disease control rate was 88.5%; docetaxel group, three cases of flapping CR, efficiency 68.8%(22/32), disease control rate of 87.5%. The efficiency of the two groups, disease control rate, the difference was not significant (P>0.05). Patients were white blood cells, platelets and decrease the incidence of anemia, the difference was not statistically significant (P> 0.05); paclitaxel liposome group flapping nausea and vomiting, rash, peripheral neuritis, the incidence of muscle pain than docetaxel group, the difference statistically significant (P<0.05),The two groups in hair loss, diarrhea, constipation, difficulty in breathing incidence was no significant difference (P>0.05). Conclusionspaclitaxel liposome plus carboplatin in advanced epithelial ovarian cancer is effective, toxicity than docetaxel and carboplatin chemotherapy in light observation worthy of further study.